BridgeMD
New treatment option for Acute Mild Ischemic Stroke
Official title Trial of Rescue Endovascular Treatment for Progressive Acute Mild Ischemic Stroke With Basilar Artery Occlusion With Extended Time Window
ClinicalTrials.gov ID: NCT06843356
What this study is testing
- What it's testing
- A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years.
- Symptoms and signs consistent with basilar artery ischemia.
- Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital...
- First-time onset meeting the criteria for mild ischemic stroke diagnosis: NIHSS score \<6.
- Symptom progression within 7 days of the first onset.
You likely can't join if
- Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic...
- mRS \>2.
- Factors in the target vessel that are expected to prevent completion of endovascular treatment.
- Multiple vessel occlusions.
- Prior imaging confirmed or investigator-assessed chronic basilar artery occlusion.
- Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.
See the full eligibility criteria
- Age ≥18 years.
- Symptoms and signs consistent with basilar artery ischemia.
- Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA); if vertebral artery occlusion is present...
- First-time onset meeting the criteria for mild ischemic stroke diagnosis: NIHSS score \<6.
- Symptom progression within 7 days of the first onset.
- Symptom progression: NIHSS score increase ≥4 points or consciousness level increase ≥2 points from the initial NIHSS score.
- Time from symptom onset to randomization \>24 hours.
- Symptom progression to randomization time ≤24 hours.
- NIHSS score ≥10 before randomization.
- pc-ASPECTS before randomization ≥ 6
- The patient or their family members are willing to comply with the protocol requirements and data collection procedures, understand, and sign the informed consent form.
- Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic transformation, new infarction in non-occluded vascular regions, severe infection...
- mRS \>2.
- Factors in the target vessel that are expected to prevent completion of endovascular treatment.
- Multiple vessel occlusions.
- Prior imaging confirmed or investigator-assessed chronic basilar artery occlusion.
- Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.
- Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.
- Gastrointestinal or urinary tract bleeding, acute myocardial infarction, cranial trauma, or major surgery within the past month.
- Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.
- Platelet count \ 2 during anticoagulation therapy (irreversible).
- Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.
- Known allergy to iodine contrast agents or other treatment-related drugs.
- Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg) (Note: Participants can be included if their blood pressure is...
- Uncontrollable blood glucose \ 22.2 mmol/L.
- Pregnancy or breastfeeding.
- Life expectancy \<6 months.
- Participation in other clinical studies that may affect outcome assessment.
- Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and/or...
The study team makes the final eligibility decision.
Where it's taking place
- Wuhu, Anhui, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wuhu, Anhui, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.